News

Merck (MRK) is back in focus after announcing that its personalized mRNA cancer vaccine, intismeran autogene, combined with Keytruda, achieved statistically significant gains in keeping high-risk melanoma from recurring or spreading in a Phase 3 trial. See our latest analysis for Merck. Merck’s recent mRNA melanoma result has arrived alongside powerful price momentum, with a 30 day share price return of 18.0% and a year to date share price return of 40.0%. The 1 year total shareholder return...

It's been a good week for healthcare, with one stock's dramatic gains driving the sector higher. Moderna stock saw its best weekly performance ever, rising over 140%. The stock surged after the pharmaceutical giant announced promising results out of trials for its cancer vaccine.

The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers

Consensus asks Eli Lilly for far less growth than it is delivering, and for margins to keep climbing from a level it only just reached.

*US equity indexes were lower this week after President Donald Trump warned of severe economic sanct

Investing.com -- A historic single-day move in biotech dominated the week, while a Treasury liquidity announcement impacted crypto and metals. Two well-known consumer names went in opposite directions on earnings.

What AbbVie sells, and who pays for it, is the useful way to read its low correlation to the index.

The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers

JEPI's 8% monthly yield looks like an obvious win over SCHD's modest payout, but the IRS treats those two income streams in ways that can quietly flip the comparison depending on where you hold them.

BMY's legacy portfolio faces generic pressure, but stronger Eliquis sales prompt a brighter 2026 revenue outlook.

Merck's (MRK) near-term catalysts remain attractive, but execution risks are underestimated at its c

Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.

The market rally flashed some bearish signals. Moderna skyrocketed on a cancer vaccine while gold and bitcoin jumped. Walmart dived.

The mRNA trade is whipsawing for a third straight session as the market keeps repricing a single trial readout with no fresh clinical information hitting the tape Friday. Friday’s swing is happening while the broader market barely moves, with the S&P 500 up 0.3% and the NASDAQ 100 up 0.1%. That backdrop shows the volatility ... Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session

MRK's growing pipeline, acquired assets and new product launches are gaining traction as it builds a diversified growth base ahead of Keytruda's 2028 LOE.

JNJ's diversified portfolio and pipeline strength offer an edge over MRK as both face patent expiration challenges.

The home to some large pharma companies and many smaller biotechs, have risen over 6% this week. The main catalyst was that Moderna and Merck announced successful trial data for a melanoma vaccine that reduces the risk patients will experience recurrence. “The read-through [from Merck and Moderna] to the others is probably indicative of a broader tailwind of pharma taking some strong actions to improve their long-term growth profiles,” says Cantor Fitzgerald analyst Carter Gould.

Moderna shares rise to close out a week of wild swings, while crypto stocks extend their recent rally.

Editor’s Note: The story has been refreshed with the latest market price action and a revised headline. Elon Musk said Wednesday that mRNA technology could fundamentally change how diseases are treated, a shift that would make medicine more of a...

↗️ Strategy (MSTR), Coinbase (COIN), American Bitcoin (ABTC): Shares in the crypto-related companies continued their climb premarket after President Trump met with digital currency leaders earlier this week.

SELLAS Life Sciences Group (SLS) is drawing fresh attention as investors reassess immune based cancer therapy stocks following Moderna and Merck’s Phase 3 cancer vaccine update and the broader oncology rally it helped spark. See our latest analysis for SELLAS Life Sciences Group. At a latest share price of $13.40, SELLAS Life Sciences Group has seen a 72.24% 90 day share price return and a very large 1 year total shareholder return. This suggests momentum has been building as attention shifts...

Moderna soared 177% Wednesday, while Merck gained 13% and the rally spread to BioNTech, Arcturus, Tempus AI and Novavax.

In a regulatory filing on August 10, pharmaceutical titan Merck & Company, Inc. (NYSE:MRK) disclosed holding 1,214,126 shares of micro-cap AI immunology firm Evaxion A/S (NASDAQ:EVAX). Evaxion shares bumped up 2% to $3.17 in early trading on the news. The position follows Merck’s September 2025 decision to exercise its option to in-license EVX-B3, Evaxion’s discovery-stage […]

Find insight on Moderna, Merck KGaA, Novonesis and more in the latest Market Talks covering the health care sector.

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 20% in the morning session after investors took profits as the stock surged over 175% in the previous session on positive clinical trial news.

(Updates with market moves at the end of the day, and other changes, if any.) US equity indexes d

US equity indexes fell on Thursday as bond yields and oil prices surged after President Donald Trump

One breakthrough could reshape the post-Keytruda earnings story

Moderna stock has delivered an exceptionally strong run over the past year, yet the valuation checks currently lean expensive and raise questions about how much optimism is already priced in. Moderna has returned very roughly 5.5x over the past 12 months, which sets a high bar for any further upside to be justified by fundamentals. Positive late stage melanoma vaccine data with Merck can support higher growth expectations for Moderna. The risk is that clinical, regulatory or execution...

Michael Reinking, Senior Market Strategist at the NYSE, recaps a week dominated by Treasury Secretary Bessent, whose doubled liquidity support buybacks reignited the debasement trade, sending gold back above 4,500 and triggering a massive crypto short squeeze that propelled Bitcoin up ~15% and Ethereum up 25%. Escalating Iran tensions pushed ICE Brent into the low 90s after a 60-day ceasefire expired, while equity markets drifted lower with the S&P 500 down ~1.5% as retail earnings disappointed broadly and healthcare surged nearly 4% on landmark cancer trial results from Merck and Moderna. Looking ahead, next week's PCE print, Nvidia earnings, and Fed Chair Warsh's first Jackson Hole speech are the marquee events to watch.